Delayed platelet recovery following autologous PBPCs transplantation after
myeloablative therapy remains an unresolved problem in lymphoma patients he
avily pretreated with several chemotherapy cycles and/or radiotherapy. In t
he present study of 50 lymphoma patients, the factors influencing platelet
recovery after myeloablative therapy followed by autologous PBPCs transplan
tation were analysed retrospectively. The median age was 42 years (range, 1
5-58). Fourteen patients had HD and 36 had NHL (13 high-grade and 23 low-gr
ade); most (80%) had stage III or IV. Twenty-two patients had received radi
otherapy to various extents before mobilization. The mean number of previou
s chemotherapy cycles was seven (range 3-24) of different regimens (range 1
-4). A median of three leukapheresis procedures (range 1-5) was performed a
fter G-CSF mobilization. Single leukapheresis was sufficient in only one pa
tient. A significant correlation was found between the BFU-E content of aut
ografts and platelet recovery after transplantation. Neither the patient's
age and sex nor the stage and grade of lymphoma had any effect on platelet
recovery after transplantation. Neither the type of myeloablative therapy u
sed or the dose of G-CSF administered after transplantation had any effect
on platelet recovery after transplantation. The type of previous chemothera
py cycles was a major adverse factor affecting the progenitor cell yield in
the autografts. Lymphoma patients previously treated with ASHAP and/or Dex
a-BEAM cycles had less progenitor cell yield. The chemotherapeutic agents u
sed in previous cycles also had a clear adverse effect on the progenitor ce
ll yield in the autografts. Lymphoma patients previously treated with cycle
s including cytarabine and/or cisplatin showed significantly less progenito
r cell yield and slower platelet recovery after transplantation. All seven
patients with delayed platelet recovery had received cytarabine and/or cisp
latin in several previous ASHAP and/or Dexa-BEAM cycles. All seven patients
had a BFU-E count of less than 1 x 10(5)/kg yield in the autografts.